Serum inhibitory factors (SIF) in patients with acute and chronic hepatitis and their clinical significance.
Serum inhibitory factors (SIF) were demonstrated in a follow-up study in eighteen patients with HBSAg-positive viral hepatitis, in nine patients with chronic persistent hepatitis (CPH) and in six patients with progressive viral hepatitis (CAH). In addition these factors were studied in fifteen patients with HBSAg-positive and HBSAg-negative CAH. SIF appeared during the incubation period up to 4 weeks before onset and disappeared in most instances within 4 weeks after onset of jaundice. Sera from patients with CPH showed no marked inhibitory activity when studied over a period of up to 3 years as compared to patients with a progressive course of hepatitis. The presense of SIF may depend upon persistence of virus, and may help to predict the development of chronic hepatitis.
D000208:Acute Disease; D000293:Adolescent; D000328:Adult; D000368:Aged; D001323:Autoantibodies; D002648:Child; D002908:Chronic Disease; D005260:Female; D005500:Follow-Up Studies; D006505:Hepatitis / Q000276:immunology*; D006506:Hepatitis A / Q000276:immunology; D006511:Hepatitis B Antigens; D006801:Humans; D037102:Lectins / Q000494:pharmacology; D008213:Lymphocyte Activation; D008297:Male; D008875:Middle Aged
D001323:Autoantibodies; D006511:Hepatitis B Antigens; D037102:Lectins